Clinical trials located in

Anderlecht

Anderlecht city is located in Belgium. Currently, 20 clinical trials are being conducted in this city.

Anderlecht, located in the Brussels-Capital Region of Belgium, is a city steeped in history and culture. It is home to the Constant Vanden Stock Stadium, where the renowned R.S.C. Anderlecht football team plays. The city boasts the Erasmus House, a museum dedicated to the life and work of the humanist Erasmus of Rotterdam. Anderlecht also has a rich agricultural past, evident in its preserved beguinage and the Collegiate Church of Saint Peter and Guido, showcasing impressive religious architecture. This blend of sports, history, and culture makes Anderlecht a unique part of Belgium’s heritage.

  • CT-EU-00116193

    Efficacy and safety study of rosnilimab in moderate to severe rheumatoid arthritis

    This study will evaluate the effectiveness and safety of Rosnilimab in patients with moderate to severe rheumatoid arthritis. Rosnilimab is an antibody that activates the PD-1 receptor, also known as ANB030. Patients will be randomly assigned to receive Rosnilimab or placebo.

    The main aim of the study is to assess changes in the 28-Joint Disease Activity Index based on the concentration of C-reactive protein (DAS28-CRP) after 12 weeks of treatment. DAS28-CRP is a validated tool that assesses disease activity based on the number of painful and swollen joints and the concentration of C-reactive protein in the blood. A reduction in DAS28-CRP indicates an improvement in the patient’s condition.

    This study aims to test whether Rosnilimab is effective and safe in the treatment of rheumatoid arthritis. If the results are promising, this drug could become a new treatment option for patients suffering from this disease.

    • placebo
    • Rosnilimab
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Testing sotatercept with regular treatment in severe pulmonary arterial hypertension patients

    This investigation seeks to assess the effect of a new drug named Sotatercept on people who are suffering from a serious lung disease called ‘Pulmonary Arterial Hypertension’ (PAH). The trial is intended for individuals with high-risk PAH who are facing significant danger of death. The main goal is to find out if incorporating Sotatercept into the standard treatment can improve outcomes and potentially enhance the chances of survival. Participants who enroll will receive either Sotatercept in addition to their current medication or a placebo alongside their regular treatment.

    • Sotatercept
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    • levoleucovorin
    • leucovorin
    • Fluorouracil
    • Bevacizumab
    • Cetuximab
    • Tucatinib
    • Oxaliplatin
    • Trastuzumab
  • Examining amivantamab’s effects on advanced colorectal cancer

    This study aims to investigate the effectiveness of a new drug called amivantamab in combating advanced or metastatic colorectal cancer. Amivantamab targets specific factors, namely EGF and MET, crucial for the growth of certain cancers, especially lung cancer, with hope of extending its efficacy to colorectal cancer. Additionally, the study aims to assess the safety of administering the drug alongside standard anti-cancer treatments. The drug will be administered in 28-day cycles, and patients will undergo regular checkups, blood tests, and other necessary assessments. The entire study duration is anticipated to be approximately 4 years and 3 months. Key measurements include monitoring improvements, such as tumor shrinkage, and documenting any encountered side effects in terms of nature, intensity, and the number of affected patients, as per standard procedures in drug trials.

    • Irinotecan
    • Oxaliplatin
    • Leucovorin
    • Fluorouracil
    • Amivantamab
  • Studying the new drug AZD8205 as a potential treatment for advanced or metastatic solid tumors

    The clinical trial is aimed at patients with advanced or metastatic solid tumors. It applies to various types of cancer, such as breast cancer, bile duct cancer, ovarian cancer and endometrial cancer.

    The study is evaluating a new compound called AZD8205, both alone and in combination with other anticancer drugs. AZD8205 is a drug-antibody conjugate, which means that the drug is linked to it. This combination helps deliver the drug directly to the cancer cells. AZD8205 will be used in combination with the drug rilvegostomig. Rilvegostomig is a biospecific antibody that binds to two different proteins (TIGIT and PD-1), which may help in the treatment of advanced solid tumors.

    The aim of the study is to assess the safety and tolerability of AZD8205 and to determine how effective it is against selected cancers. Patients will be monitored for side effects and their body’s response to treatment to help determine the best dosage and determine the maximum tolerated dose.

    The trial is open to adult patients with certain types of cancer who meet eligibility criteria. Researchers will evaluate both the positive and negative effects of the drug to find out whether it is suitable for treating these specific types of cancer.

    • AZD8205- new potential medication for solid tumors
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    • CAPEOX
    • Dostarlimab
    • FOLFOX
  • Comparing treatments for new Large B-cell lymphoma patients

    The trial aims to analyze and compare two drug treatments for people who have a large B-Cell Lymphoma, a kind of cancer that affects a certain type of white blood cells, and have not yet started their treatment. The first treatment is a combination of glofitamab, polatuzumab vedotin, and other common drugs used for this condition: rituximab, cyclophosphamide, doxorubicin, and prednisone. The second treatment is the same, but doesn’t include the glofitamab. The goal is to understand which treatment is more effective and safer for the patient.

    • Prednisone
    • Polatuzumab vedotin
    • Glofitamab
    • Doxorubicin
    • Cyclophosphamide
    • Rituximab
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    • Sotatercept
  • Study of Tucatinib, Trastuzumab and Pertuzumab in the treatment of HER2+ metastatic breast cancer

    The study is aimed at patients with HER2-positive breast cancer whose disease has spread locally, i.e. close to where it started, and cannot be surgically removed, or has spread to other parts of the body. Treatment in this study includes a combination of drugs: tucatinib (also known as TUKYSA, ONT-380, ARRY-380), trastuzumab (Herceptin, Herceptin Hylecta), and pertuzumab (Perjeta). Some patients will receive a placebo instead of tucatinib.

    All patients will receive trastuzumab and pertuzumab, plus either tucatinib or placebo. Trastuzumab is administered intravenously (IV) or subcutaneously, and pertuzumab is administered intravenously. In some cases, trastuzumab and pertuzumab may be administered subcutaneously in combination.

    The aim of the study is to check whether tucatinib in combination with trastuzumab and pertuzumab works better than placebo. This will also check what side effects may occur while taking this drug combination. Side effects are any adverse effects a drug may have on the body in addition to treating the disease.

    The study includes patients who have already undergone 4-8 cycles of pre-treatment with trastuzumab, pertuzumab and taxane as first-line treatment for advanced breast cancer, and do not show disease progression after completion of this pre-therapy. Patients can have both positive and negative hormone receptor status.

    • Pertuzumab
    • Tucatinib
    • Trastuzumab
  • Studying rilvegostomig in the treatment of advanced or metastatic lung cancer

    This clinical trial evaluates rilvegostomig, a new drug for advanced non-small cell lung cancer (NSCLC). The study involves people with stage III or IV NSCLC and explores if rilvegostomig is safe and effective. It’s conducted in several parts, including dose escalation and expansion, to determine the best dose and its impact on the cancer. The trial measures how patients respond to the treatment and monitors for any side effects.

    • Rilvegostomig
  • Study of lacutamab in T-cell lymphoma

    This trial involves a medication called lacutamab, which will be given to patients who have a type of blood cancer known as peripheral T-cell lymphoma, and their disease has either come back after previous treatment or didn’t respond at all. Some patients in the study will receive lacutamab in combination with a common chemotherapy drugs gemcitabine and oxaliplatine, while others will get only gemcitabine and oxaliplatine. A key aim of this study is to find out if lacutamab is both safe and effective. The study is designed not to compare the two treatments directly, but to check our assumptions for deciding the number of people for the trial. The number of participants getting lacutamab is bigger.

    • Lacutamab
    • Oxaliplatine
    • Gemcitabine
  • Study on new medicine and immune drugs for hard-to-treat tumors

    The safety and efficacy of a new drug, Zanzalintinib (XL092) is currently evaluated in investigation in a trial designed for individuals with inoperable solid tumors or those that have metastasized. The drug may be administered as a standalone treatment or in combination with other medications designed to stimulate the immune system’s response to combat cancer. The initial phase focuses on determining the appropriate dosage for Zanzalintinib. Subsequently, the trial aims to assess the effectiveness of Zanzalintinib and companion drugs in reducing tumor size and enhancing survival rates. Throughout the study, potential adverse reactions to the drug will also be monitored. During the second stage, the evaluation of Zanzalintinib will be expanded to analyze outcomes in patients with specific cancer types. The objective is to investigate whether the drug leads to a slower progression of cancer and a reduction in tumor size for individuals with these particular types of cancer.

    • Relatlimab
    • Zanzalintinib/XL092
    • Nivolumab
    • Ipilimumab
  • Testing a new drug for advanced cancer or lymphomas

    In this research, the researchers are testing a new drug called OSE-279 that might help fight cancer. The researchers are looking for people who have very advanced forms of cancer, like tumors or lymphoma, which are not responding to other treatments. This study has two main parts. First, it is important to try to find the right dose of the drug that is safe but also effective. Then, the researchers expand the trial with more people to see how well it works. Main measurements are how much the cancer shrinks (responses), how long it stays like that (response duration), to evaluate the drug’s effectiveness.

    • OSE-279
  • Testing Nipocalimab’s effect on adults with Muscle Weakness

    This study is about a new drug called nipocalimab for patients with a disease called Myasthenia Gravis (MG). MG patients feel weak in their muscles, and nipocalimab potentially could help to lessen this weakness. The drug functions by attaching itself to certain components of the blood to lessen the reaction causing muscle weakness. This large-scale study will take place in multiple hospitals and is organized in different phases including initial checks (4 weeks), treatment (24 weeks) and follow-ups (up to 2 years). It will be measured how well the treatment works through daily activity scores and strength tests.

    • Nipocalimab
  • Study of SAR445514 for patients with relapsed/refractory multiple myeloma and light-chain amyloidosis.

    This comprehensive study delves into SAR445514’s potential to treat two serious disorders: relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA). The trial is structured into three detailed phases. Initially, the dose-escalation phase aims to identify the safest dose level. Following this, the dose-optimization phase seeks to determine the most effective dose. Finally, the expansion phase rigorously evaluates the therapeutic impact of SAR445514 at the optimized dose. Throughout these phases, the study meticulously monitors participant responses, side effects, and overall health changes. The ultimate goal is to establish a new, effective treatment option, enhancing the quality of life and survival prospects for individuals battling these complex and challenging conditions.

    • SAR445514- new potential medication for advanced blood cancers
  • Testing new medication effect on advanced cancer

    This study involves the new medicine and is designed for patients who have advanced or metastatic tumors, meaning tumors that have spread. It’s a two-part study. The first part is to discover the safest and most effective dose of new medicin called XON7. The second part is to test how well XON7 works on different tumor types. During the study, the researchers will monitor the side effects that might happen in the first treatment period. It is also important to check several things in blood, like the number of blood cells and the levels of different elements and enzymes. Also, two things which will be observed are blood pressure and heart rhythm. Sometimes, blood pressure can go up or heart rhythm can change, which this medicine may cause. Additionally, the researchers are interested in seeing the proportion of patients who had their tumors completely disappear or decrease in size. And also check how much of XON7 is in the blood at different times.

    • XON7- new potential medication for advanced cancer
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    • Mavacamten
  • Study of new medicine role in treating advanced solid tumours

    This study known as DT-9081 is designed for people dealing with advanced or returning tumors. The purpose of the study is to find out the right amount of DT-9081 medicine that can be given to a participant. Once that is known, more people will take the medicine to see if it works well and is safe. The medicine will be given once a day by mouth, but that can be changed depending on any bad reactions. The study will also check how the body handles the medicine and whether it helps to stop or slow down the growth of the tumor.

    • DT-9081
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab

See more clinical trials in other cities in Belgium:

.